Global registry for Takayasu arteritis patients
Part of Heart & circulation, Skin clinical trials.
This study collects medical information from patients diagnosed with Takayasu arteritis, a rare disease affecting large blood vessels. By joining, you help researchers better understand this condition and improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Takayasu arteritis (confirmed by standard medical criteria)
- You must be willing to share your medical history and any health changes with the research team
- You must sign a written consent form showing you understand the study and agree to participate
- You must be able to follow the study requirements for the duration you're enrolled
- If you are under 18, your parent or legal guardian must also agree and sign the consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information and blood samples (biomarkers) to better understand Takayasu arteritis and how active it is. It may help researchers find tests that support diagnosis and track disease activity.
This study tests a new ultrasound scoring system to monitor disease activity in people with Takayasu arteritis. It aims to see if ultrasound can reliably track the disease, which might help guide treatment decisions.
This UK-based study uses a questionnaire to learn about how people with Takayasu arteritis (a rare type of vasculitis) are treated and what they think about their care. If you have TAK, your answers can help doctors understand how to better manage this condition.
This trial tests an oral medication called deucravacitinib (which is already used for psoriasis) to see if it can calm inflammation in Takayasu's arteritis. If you have active disease despite current treatment, this may offer a new option to help control symptoms and prevent damage.
This trial is testing two new medications, vunakizumab and ivarmacitinib, to see if they are safe and effective at controlling active Takayasu's arteritis. These medicines work differently from your current treatment, so they might help reduce inflammation and prevent more damage to your blood vessels.
This study looks at different types of blood vessel inflammation (vasculitis) to learn more about why they happen and how they progress. By joining, you may help doctors better understand these conditions and improve future treatments.
Hear when a new Takayasu Arteritis (TAK) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.